Brief: Sprint Bioscience Q2 Operating Loss Widens To SEK 6.8 Mln
Aug 27 (Reuters) - Sprint Bioscience AB SPRINT.ST: Q2 NET SALES SEK 13.9 (16.7) MILLION Q2 OPERATING PROFIT SEK -6.8 (-5.6) MILLION Source text: ID:nMFN6YfFCb Further company coverage: SPRINT.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Sprint Bioscience AB
See all newsBrief: Sprint Bioscience Q1 Operating Loss SEK 14.3 Mln
Brief: Sprint Bioscience Completes Strategic Evaluation Of STK25 Program
Brief: Sprint Bioscience Appoints Jenni Björnulfson As CFO
Brief: Sprint Bioscience Reports Positive Proof-Of-Concept Results From Program In CKD
Brief: Sprint Bioscience Reports Positive Results From The Vrk1 Program